Calcineurin inhibitors: 40 years later, can’t live without
The DOI matches its Crossref record; 87 of the 90 references it cites were found in a registry or an index.
Abstract
Calcineurin inhibitors (CNIs) revolutionized the field of organ transplantation and remain the standard of care 40 years after the discovery of cyclosporine. The early impressive results of cyclosporine in kidney transplant recipients led to its subsequent use in other organ transplant recipients and for treatment of a variety of autoimmune diseases as well. In this review, we examine the discovery of CNIs, their mechanism of action, preclinical and clinical studies with CNIs, and the usage of CNIs in nontransplant recipients. We review the mechanisms of renal toxicity associated with CNIs and the recent efforts to avoid or reduce usage of these drugs. Although minimization strategies are possible, safe, and of potential long-term benefit, complete avoidance of CNIs has proven to be more challenging than initially thought.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calcineurin inhibitors, including ciclosporin and tacrolimus, inhibit T cell proliferation and activation through targeting IL-2 (58).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [58]
In the citing paper
“Ciclosporin and tacrolimus are immunosuppressants that inhibit calcineurin, a key signaling phosphatase, by binding to their respective immunophilins - cyclophilin and FKBP12 (76).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [76]
In the citing paper
“A major downstream effect is suppression of interleukin (IL)-2 transcription, thereby inhibiting T cells differentiation, survival, and subsequent antibody production and CTL activities via effector TH cells.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [76]
Citations
Cites
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325 · cited 2×
“Regulatory T cells have been shown to be essential for immune tolerance induction in transplantation (16).”
BackgroundTRANSCRIPTION FACTORS OF THE NFAT FAMILY:Regulation and Function
Rao, A., Luo, C., & Hogan, P. G. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.707 · Cited by 2,603 · cited 1×
“scriptional activation of genes encoding cytokines, including IL-2 and IL-4, and CD40 ligand (12).”
BackgroundThe Natural History of Chronic Allograft Nephropathy
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Allen, R. D. M., & Chapman, J. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020009 · Cited by 1,949
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
Creighton, T. E. (1992) · Cited by 1,583
Biological effects of cyclosporin A: A new antilymphocytic agent
Borel, J. F., Feurer, C., Gubler, H. U., & Stähelin, H. (1976) · Agents and Actions · doi:10.1007/bf01973261 · Cited by 1,509 · cited 1×
“Many mechanisms were suggested, including an imbalance between vasoconstrictive and vasodilatory mediators (46), an activation of the renin-angiotensin-aldosterone system (47), an increase in the release of endothelin (5), an increase in free radicals (48), and a sympathetic nerve activation in the native kidneys thro…”
BackgroundPirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Calne, R. Y., Rolles, K., Thiru, S., Mcmaster, P., Craddock, G. N., Aziz, S., White, D. J. G., Evans, D. B., Dunn, D. C., Henderson, R. G., et al. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92440-1 · Cited by 1,083
CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS
Calne, R. Y., Thiru, S., Mcmaster, P., Craddock, G. N., White, D. J. G., Evans, D. B., Dunn, D. C., Pentlow, B. D., & Rolles, K. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91970-0 · Cited by 1,002 · cited 1×
“The nephrotoxicity of cyclosporine, reported by Calne and colleagues in the early human studies, remains a major concern for the medical community today (21).”
BackgroundVincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957 · cited 2×
“The cardiovascular and metabolic profiles were better in belatacept groups compared with patients receiving cyclosporine (70).”
Background
Research works printed but not linked: 1
- Klee, 1988, Calcineurin, Adv. Enzymol. Relat. Areas Mol. Biol., 61, 149
Cited by
Items 101–200 of 337
Lee, H., Kim, L.-K., & Choi, J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.006 · Cited by 20
Kuo, P., Rau, C., Wu, S., Lin, C.-W., Huang, L., Lu, T., Wu, Y.-C., Wu, C., Tsai, C.-W., & Hsieh, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179628 · Cited by 21
“FK506 binds to FK506-binding proteins, inhibits the calcineurin/the nuclear factor of activated T cells pathway (NFAT) pathways, and thus suppresses IL-2 gene transcription in T lymphocytes, which is required for T-cell proliferation [33,34].”
BackgroundA Systematic Review of Adherence to Immunosuppression among Pediatric Heart Transplant Patients
Nassetta, K., Hussain, T., Gambetta, K. E., Le, K. T., O’Dwyer, L., & Badawy, S. M. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9050165 · Cited by 24
“Most post-transplant immunosuppression regimens include a calcineurin inhibitor (CNI) and an antiproliferative agent [2,4].”
BackgroundDaprodustat prevents cyclosporine-A–mediated anemia and peritubular capillary loss
Labes, R., Brinkmann, L., Kulow, V. A., Roegner, K., Mathia, S., Balcerek, B., Persson, P. B., Rosenberger, C., & Fähling, M. (2022) · Kidney International · doi:10.1016/j.kint.2022.04.025 · Cited by 23
Loss of myosin Vb promotes apical bulk endocytosis in neonatal enterocytes
Engevik, A. C., Kaji, I., Postema, M. M., Faust, J. J., Meyer, A. R., Williams, J. A., Fitz, G. N., Tyska, M. J., Wilson, J. M., & Goldenring, J. R. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201902063 · Cited by 21
“To determine the effects of calcineurin on bulk endocytosis of the apical membrane in Myo5b-deficient enterocytes, cyclosporin A (an inhibitor of calcineurin; Azzi et al., 2013) was administered to enteroids.”
BackgroundSerine/threonine phosphatases in osteoclastogenesis and bone resorption
Karkache, I. Y., Damodaran, J. R., Molstad, D. H. H., & Bradley, E. W. (2020) · Gene · doi:10.1016/j.gene.2020.145362 · Cited by 23
“Calcineurin consists of the catalytic subunit Calcineurin A (CNA) and the regulatory subunit Calcineurin B (CNB) (28).”
BackgroundInfluentialSharma, M., Fu, M. P., Lu, H. Y., Sharma, A., Modi, B. P., Michalski, C., Lin, S. X., Dalmann, J., Salman, A., Bel, K. L. D., et al. (2022) · Blood · doi:10.1182/blood.2022015674 · Cited by 22
Targeting the immune system to treat hypertension: where are we?
Gooch, J. L., & Sharma, A. C. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000052 · Cited by 19
Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review
Ohmoto, A., & Fuji, S. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1652590 · Cited by 19
“CyA is practically used in recipients of organ transplantation including alloSCT, and in patients with autoimmune diseases such as rheumatoid arthritis, psoriasis or ulcerative colitis [22].”
BackgroundBuchholz, B. M., Ferguson, J., Schnitzbauer, A. A., Nightingale, P., Schlitt, H. J., Geissler, E. K., Mirza, D. F., & the International SiLVER study group (2019) · Transplantation · doi:10.1097/tp.0000000000002980 · Cited by 21
Qin, R., Qin, J., Li, X., Xu, Z., He, P., Yuan, X., Sun, C., & Nashan, B. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-438 · Cited by 19
“At the same time, these regimens are associated with adverse events, such as renal dysfunction, neurotoxicity, and diabetes (50).”
BackgroundTremor Induced by Cyclosporine, Tacrolimus, Sirolimus, or Everolimus: A Review of the Literature
Shukla, A. W., Lunny, C., Mahboob, O., Khalid, U., Joyce, M., Jha, N., Nagaraja, N., & Shukla, A. M. (2023) · Drugs in R&D · doi:10.1007/s40268-023-00428-4 · Cited by 20
“The intracellular binding proteins for both cyclosporine (cyclophilin) and tacrolimus (FK binding protein-12 or FKBP-12) [100, 101] are enriched in the central nervous system [102].”
BackgroundSubramaniam, S., Fares‐Gusmao, R., Sato, S., Cullen, J. M., Takeda, K., Farci, P., & McGivern, D. R. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011664 · Cited by 19
Side Effects of Immunosuppressant Drugs After Liver Transplant
Gabrielli, F., Bernasconi, E., Toscano, A., Avossa, A., Cavicchioli, A., Andreoné, P., & Gitto, S. (2025) · Pharmaceuticals · doi:10.3390/ph18030342 · Cited by 22
“Tacrolimus (FK506) was isolated from the soil fungus Streptomyces tsukubaensis [25].”
Role in Calcineurin Inhibitors for Inflammatory Bowel Disease in the Biologics Era
Nakase, H., Yoshino, T., & Matsuura, M. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000130 · Cited by 17
“CsA is an immunosuppressive drug largely used to prevent acute rejection after solid organ transplantation.(8,9) It is also used in the prophylaxis and treatment of acute and chronic graft-versus-host disease after hematopoietic stem cell transplantation or to improve the engraftment in nonmyeloablative and reduced in…”
BackgroundA reasoned approach to the treatment of autoimmune hepatitis
Vergani, D., Beretta‐Piccoli, B. T., & Mieli‐Vergani, G. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.05.033 · Cited by 19
“Activated NFATc is then translocated into the nucleus, where it upregulates the expression of IL-2, which, in turn, stimulates the growth and differentiation of the T cell response [76] .”
Advancement in therapeutic strategies for immune-mediated oral diseases
Patil, S., Mustaq, S., Hosmani, J., Khan, Z. A., Yadalam, P. K., Ahmed, Z. H., Bhandi, S., & Awan, K. H. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101352 · Cited by 21
How do kinases contribute to tonicity-dependent regulation of the transcription factor NFAT5?
Zhou, X. (2016) · World Journal of Nephrology · doi:10.5527/wjn.v5.i1.20 · Cited by 23
Sekiya, T., Kasahara, H., Takemura, R., Fujita, S., Kato, J., Doki, N., Katayama, Y., Ozawa, Y., Takada, S., Eto, T., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100808 · Cited by 16
Hefler, J., Marfil‐Garza, B. A., Campbell, S., Freed, D. H., & Shapiro, A. M. J. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-618 · Cited by 16
“The immunosuppressant effect of CsA is a result of calcineurin inhibition (6).”
Singh, D., Qasam, I., Paudwal, G., Kotwal, P., Behera, C., Kumar, A., Gupta, A. P., Nandi, U., Yadav, G., Gupta, P. N., et al. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00946 · Cited by 16
Sattler, A., Thiel, L. G., Ruhm, A. H., Bergmann, Y., Dornieden, T., Choi, M., Halleck, F., Friedersdorff, F., Eurich, D., & Kotsch, K. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16122 · Cited by 17
Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil
Gomes, R. M., Guerra, A. A., de Lemos, L. L. P., Costa, J. D. O., Almeida, A. M., Campos, J. Á. D. B., Filho, C. S., Cherchiglia, M. L., Andrade, E. I. G., Godman, B., et al. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1190270 · Cited by 16
“Both drugs are associated with long-term nephrotoxicity, but tacrolimus is associated with a higher incidence of post-transplant diabetes mellitus; whereas cyclosporine is associated with hyperlipidemia and hypertension(15, 20, 21).”
BackgroundChen, X.-T., Li, J., Deng, R., Yang, S., Chen, Y.-Y., Chen, P., Wang, Z., Huang, Y., Wang, C., & Huang, G. (2019) · Bioscience Reports · doi:10.1042/bsr20182058 · Cited by 16
Haam, S., Noda, K., Philips, B. J., Harano, T., Sánchez, P. G., & Shigemura, N. (2020) · Transplantation · doi:10.1097/tp.0000000000003237 · Cited by 16
“Regarding this study, CyA is well known as an immunosuppressant and its effects are based on inhibition of calcineurin signaling in T cells.(49) Based upon this current study, we acknowledge that we do have limited data about the effects of CyA on immune suppression in the lungs during EVLP.”
BackgroundPhenomenology and Physiology of Tacrolimus Induced Tremor
Shukla, A. W., Lunny, C., Hisham, I., Cagle, J. N., Joyce, M., Santos, A. H., & Shukla, A. M. (2023) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.725 · Cited by 17
Saikia, G., Gogoi, S. R., Boruah, J. J., Ram, B. M., Begum, P., Ahmed, K., Sharma, M., Ramakrishna, G., Ramasarma, T., & Islam, N. S. (2017) · ChemistrySelect · doi:10.1002/slct.201700935 · Cited by 15
Metabolic Drug Interactions with Immunosuppressants
Monostory, K. (2018) · InTech eBooks · doi:10.5772/intechopen.74524 · Cited by 15
“Ciclosporin A is an 11-amino acid cyclopeptide that blocks the production of IL-2 by inhibition of calcineurin and, as a consequence, the activation of T-cells (Figure 1) [31].”
BackgroundCalmodulin: a highly conserved and ubiquitous Ca2+ sensor
Sobue, K. (2024) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.100.025 · Cited by 17
Shin, S., Kim, M.-W., Cho, K., & Nguyen, L. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-46592-z · Cited by 15
JAK3 inhibitor-based immunosuppression in allogeneic islet transplantation in cynomolgus monkeys
Kim, J. M., Shin, J., Min, B., Kang, S., Yoon, I., Chung, H., Kim, J., Hwang, E., Ha, J., & Park, C. (2019) · Islets · doi:10.1080/19382014.2019.1650580 · Cited by 15
Identification and Validation of New Interleukin-2 Ligands Using DNA-Encoded Libraries
Gironda-Martínez, A., Gorre, É. M. D., Prati, L., Gosalbes, J.-F., Plaza, S. D., Cazzamalli, S., Samain, F., Donckèle, E. J., & Neri, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01693 · Cited by 13
Papasavvas, I., Tuğal-Tutkun, İ., & Herbort, C. P. (2022) · Pharmaceuticals · doi:10.3390/ph15040398 · Cited by 14
Treatment of Myasthenia Gravis
Kaminski, H. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-73585-6_11 · Cited by 15
Examining the Association between Immunosuppressants and Wound Healing: A Narrative Review
Appoo, A., Christensen, B. L., & Somayaji, R. (2024) · Advances in Skin & Wound Care · doi:10.1097/asw.0000000000000127 · Cited by 14
Salvage Therapies for Autoimmune Hepatitis: A Critical Review
Kemp, W. W., & Roberts, S. K. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1607453 · Cited by 15
Park, C., Kwon, D. H., Hwang, S. J., Han, M. H., Jeong, J.-W., Hong, S. H., Cha, H., Hong, S. H., Kim, G., Lee, H., et al. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16061044 · Cited by 13
Immunosuppression Affects Neutrophil Functions: Does Calcineurin-NFAT Signaling Matter?
Vymazal, O., Bendíčková, K., Zuani, M. D., Vlková, M., Kohoutková, M. H., & Frič, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.770515 · Cited by 15
“The pro-inflammatory pathways operating in neutrophils may also be directly affected: calcineurin inhibitors (CNI) suppress activation of the CN-NFAT pathway and are now widely used in transplantation medicine to prevent graft versus host disease and also to treat autoimmune disorders as psoriasis, severe atopic derma…”
BackgroundCalcineurin associates with centrosomes and regulates cilia length maintenance
Tsekitsidou, E., Wong, C. J., Ulengin-Talkish, I., Barth, A. I. M., Stearns, T., Gingras, A., Wang, J., & Cyert, M. (2023) · Journal of Cell Science · doi:10.1242/jcs.260353 · Cited by 15
Episodic Hypoxia Promotes Defence Against Cellular Stress
Heß, V., Kasim, M., Mathia, S., Persson, P. B., Rosenberger, C., & Fähling, M. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000073 · Cited by 15
Lung allocation for transplant: The European perspective
Holm, A. M., Immer, F. F., & Benden, C. (2020) · Clinical Transplantation · doi:10.1111/ctr.13883 · Cited by 13
Swingle, M. R., & Honkanen, R. E. (2014) · Assay and Drug Development Technologies · doi:10.1089/adt.2014.603 · Cited by 12
“Another possible assay approach would be to utilize the fluorogenic substrate 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP), which is commercially available from Life Technologies (also available from the same company in a phosphatase assay kit; EnzChek (cid”
Calcineurin Participation in Hebbian and Homeostatic Plasticity Associated With Extinction
Reyes-García, S. E., & Escobar, M. L. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.685838 · Cited by 15
“Calcineurin was originally described for its role on the activation of the nuclear factor of activated T-cells (NFAT), this regulation is linked to apoptosis, cardiac pathology and immune response in the kidney (Azzi et al., 2013).”
BackgroundRole of Tacrolimus C/D Ratio in the First Year After Pediatric Liver Transplantation
Prušinskas, B., Ohlsson, S., Kathemann, S., Pilic, D., Kampmann, K., Büscher, R., Paul, A., Pape, L., Hoyer, P. F., & Lainka, E. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.659608 · Cited by 12
Therapeutics for the Management of Cytokine Release Syndrome in COVID-19
Bhaskar, R., Sinha, J. K., Ghosh, S., Durgvanshi, S., & Han, S. S. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220707114121 · Cited by 11
Doesch, A. O., Helmschrott, M., Beckendorf, J., Akyol, C., Ruhparwar, A., Schmack, B., Erbel, C., Gleissner, C. A., Akhavanpoor, M., Ehlermann, P., et al. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s68542 · Cited by 12
“TAC and cyclosporine A (CSA) have different chemical structures, but the main mechanism of action is similar.(7) As TAC needs a 100-times lower concentration, possible favorable effects regarding prevention of allograft rejection might be explained.”
mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis
Eskandari, S. K., Allos, H., Dulaijan, B. S. A., Melhem, G., Sulkaj, I., Alhaddad, J. B., Saad, A. J., Deban, C. A., Chu, P., Choi, J. Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.899975 · Cited by 13
“Importantly, CsA belongs to a drug class known as calcineurin inhibitors (CNIs), which are archetypal immunosuppressants that continue to be used for solid organ transplantation to this day (28, 29).”
BackgroundSelf-citationConnolly, S., Quasi-Woode, D., Waldron, L., Eberly, C. L., Waters, K., Muller, E. M., & Kingsbury, T. J. (2018) · Genetics · doi:10.1534/genetics.118.300911 · Cited by 15
“Calcineurin inhibitors FK506 (tacrolimus) and cyclosporin A are widely used clinically to prevent allograft rejection in transplant patients and treat inflammatory skin diseases (Musson et al. 2012; Azzi et al. 2013; Nygaard et al. 2017).”
BackgroundBarakat, M. T., Khalid, A., Yu, M., Ding, Y., Murayi, J. O., Jayaraman, T., Poropatich, R., Akshintala, V., Juakiem, W. Y., Wen, L., et al. (2022) · Pancreatology · doi:10.1016/j.pan.2022.07.003 · Cited by 11
Datrino, L. N., Boccuzzi, M. L., Silva, R. M., Castilho, P. H. B. T., Riva, W. J., Rocha, J. S., & Tustumi, F. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.05.014 · Cited by 12
Heart Transplant Rejection: From the Endomyocardial Biopsy to Gene Expression Profiling
Farcas, A. O., Stoica, M. C., Maier, I. M., Maier, A. C., & Sin, A. I. (2024) · Biomedicines · doi:10.3390/biomedicines12081926 · Cited by 17
“By binding to intracellular proteins (cyclophilin for Cyclosporine and FKBP-12 for Tacrolimus), CNIs prevent the activation of calcineurin, thereby blocking NFAT dephosphorylation and the subsequent production of IL-2, leading to suppressed T-cell activation and proliferation [67].”
BackgroundNFAT1 Regulates Systemic Autoimmunity through the Modulation of a Dendritic Cell Property
Chae, C.-S., Kim, G.-C., Park, E. S., Lee, C., Verma, R. P., Cho, H., Jun, C., Yoo, Y. J., & Im, S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700882 · Cited by 11
“used as immunosuppressive drugs to prevent graft rejection and treat autoimmune diseases (5).”
BackgroundYu, F., Courjaret, R. J., Elmi, A. A., Alcantara-Adap, E., Orie, N. N., Zghyer, F., Hubrack, S., Hayat, S. A., Asaad, N., Worgall, S., et al. (2022) · The Journal of Physiology · doi:10.1113/jp283811 · Cited by 9
“, 2016), and because diabetes is a common side effect of chronic immunosuppression (Azzi et al., 2013; Bamgbola, 2016; Chakkera et al., 2017), we next tested whether hypomorph mice develop diabetes.”
BackgroundA zebrafish model for calcineurin-dependent brain function
Edmister, S. T., Ibrahim, R., Kakodkar, R., Kreiling, J. A., & Créton, R. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113544 · Cited by 11
Cyclosporine Affects the Main Virulence Factors of Cryptococcus neoformans In Vitro
de Andrade, I. B., Corrêa-Junior, D., Alves, V., Figueiredo‐Carvalho, M. H. G., dos Santos, M. V. F., Almeida, M. D. A., Valdez, A. F., Nimrichter, L., Almeida‐Paes, R., & Frasés, S. (2023) · Journal of Fungi · doi:10.3390/jof9040487 · Cited by 13
Role of Protein Phosphatases in Tumor Angiogenesis: Assessing PP1, PP2A, PP2B and PTPs Activity
Fonódi, M., Nagy, L., & Boratkó, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136868 · Cited by 11
“…in the context of developing tumor vasculature [230]. the small number of PTPs that have been identified as essential modulators of angiogenesis, offering an opportunity to discover novel therapeutic targets for obstructing angiogenesis, mainly in the context of developing tumor vasculature [230].”
BackgroundA review of landmark studies on maintenance immunosuppressive regimens in kidney transplantation
Udomkarnjananun, S., Schagen, M. R., & Hesselink, D. A. (2024) · Asian Biomedicine · doi:10.2478/abm-2024-0015 · Cited by 15
“As a result, the standard regimen of TAC/MPA/corti - costeroids remains the cornerstone of immunosuppression for kidney transplantation, as it has consistently demonstra - ted superior outcomes in terms of reducing allograft rejection and improving allograft survival [144].”
BackgroundImmunosuppressant imprecision: multidirectional effects on metabolism and microbiome
Kensiski, A., Gavzy, S. J., Wu, L., Mas, V. R., Ma, B., & Bromberg, J. S. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00178-24 · Cited by 11
“…inhibitors (CNIs), including tacrolimus, inhibit calcineurin, which results in the inhibition of cytoplasmic nuclear factor of activated T cells (NFAT), thereby blocking T cell activation, Treg proliferation, and function (9, 10), and naïve B cell proliferation and plasmablast differentiation (8).”
Cheng, C.-H., Lee, C.-F., Oh, B. C., Furtmüller, G. J., Patel, C. H., Brandacher, G., & Powell, J. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00572 · Cited by 12
Cherikh, W. S., Kou, T. D., Foutz, J., Baker, T. J., & Gomez‐Caminero, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0311935 · Cited by 12
Viral-mediated gene therapy in pediatric neurological disorders
Peng, J., Zou, W., Wang, X., Zhang, Z., Huo, R., & Yang, L. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-022-00669-4 · Cited by 11
“Researchers have tried several immunosuppressants (ISs), including corticosteroids [77], rapamycin [78], mycophenolate mofetil (MMF) [79], calcineurin inhibitors [80], rituximab (RTX) [81], rabbit anti-thymocyte globulin (ATG) [82], and even anti-malarials [83].”
Yoon, J. G., Song, S. H., Choi, S., Oh, J., Jang, I., Kim, Y. J., Moon, S., Kim, B.-J., Cho, Y., Kim, H. K., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003660 · Cited by 9
“TAC and cyclosporine A are both classified as calcineurin inhibitors, which block the activation, proliferation, and differentiation of T lymphocytes, thus eliciting immune suppression.(1) TAC has gradually replaced cyclosporine A as the primary immunosuppressant of choice for allogenic transplants, owing to its Origi…”
BackgroundWang, H., Shi, Y., Zhou, X., Zhang, L., Yang, A., Zhou, D., & Ma, T. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09890-5 · Cited by 9
“Drugs that inhibit NFAT, such as tacrolimus and cyclosporin A (CSA) that inhibit phosphatases, have demonstrated anticancer activity that is accompanied by immunosuppressive side effects (Durnian et al. 2007; Azzi et al. 2013).”
BackgroundDavison, J. R., Hadjithomas, M., Romeril, S. P., Choi, Y. J., Bentley, K. W., Biggins, J. B., Chacko, N., Castaldi, M. P., Chan, L. K., Cumming, J. N., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01095 · Cited by 9
Woon, T. H., Tan, M. J. H., Kwan, Y. H., & Fong, W. W. S. (2024) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2024.103017 · Cited by 8
Ong, E., Clottes, P., Léon, C., Guedouari, H., Gallo-Bona, N., Lo-Grasso, M., Motter, L., Bolbos, R. I., Ovize, M., Nighogossian, N., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00549 · Cited by 10
“Finally, we cannot assert if CsA action was acting directly on the mPTP or via its known effect on calcineurin [36,37].”
Inhibitory Effects of Urtica thunbergiana Ethanol Extract on Atopic Dermatitis-Induced NC/Nga Mice
Ngo, H. T. T., Fang, M., Hwang, E., Kim, Y., Park, B., Seo, S. A., Quynh, N., Nguyen, Q. T. N., & Yi, T. (2020) · Antioxidants · doi:10.3390/antiox9030197 · Cited by 9
“Tacrolimus, an immunosuppressive agent, is an alternative to topical corticosteroids, as a calcineurin inhibitor [6,7].”
BackgroundKutschat, A. P., Johnsen, S. A., & Hamdan, F. H. (2021) · Cells · doi:10.3390/cells10050966 · Cited by 10
Lower versus higher starting tacrolimus dosing in kidney transplant recipients
Chua, J. C. M., Mount, P. F., & Lee, D. (2022) · Clinical Transplantation · doi:10.1111/ctr.14606 · Cited by 8
Extracellular Vesicles: The Future of Diagnosis in Solid Organ Transplantation?
Romero-García, N., Huete-Acevedo, J., Mas‐Bargues, C., Sanz‐Ros, J., Dromant, M., Badenes, R., & Borrás, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065102 · Cited by 10
Habeeb, E. A., Gabardi, S., Townsend, K. R., & Kim, M. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.04.028 · Cited by 8
“CNIs are mainstays of maintenance immunosuppressants in solid organ transplant recipients.(9) Following oral administration, CNI are extensively metabolized by CYP3A5 and CYP3A4 in gut and liver, and they are also substrates of P-gp, conferring a high potential for DDI.”
BackgroundSwingle, M. R., Volmar, C., Saldanha, S. A., Chase, P. S., Eberhart, C., Salter, E. A., D’Arcy, B. M., Schroeder, C. E., Golden, J. E., Wierzbicki, A., et al. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116668852 · Cited by 8
Michaud, L., Ludwig, G., Berney, S., Rodrigues, S. D., Niquille, A., Santschi, V., Favre, A.-S., Lange, A.-C., Michels, A. A., Vrijens, B., et al. (2016) · Pharmacy Practice · doi:10.18549/pharmpract.2016.04.822 · Cited by 10
PREVALENCE AND RISK FACTORS OF HYPERKALEMIA AFTER LIVER TRANSPLANTATION
Ribeiro, H. S., OLIVEIRA, M. C., Anastácio, L. R., Generoso, S. D. V., Lima, A. S., & Correia, M. I. T. D. (2018) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-672020180001e1357 · Cited by 8
Zhu, J., Campagne, O., Torrice, C., Flynn, G., Miller, J. A., Patel, T., Suzuki, O., Ptachcinski, J. R., Armistead, P. M., Wiltshire, T., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.12956 · Cited by 8
“It has been shown that getting to target tacrolimus steady-state trough concentrations quicker have been associated with a lower incidence of aGVHD and tacrolimus-induced toxicities.29,30 Therefore, to explore optimized tacrolimus dosing for patients receiving allogeneic HCT, the primary objectives of this study were…”
BackgroundMethodInfluentialKurakado, S., Matsumoto, Y., Yamada, T., Shimizu, K., Wakasa, S., & Sugita, T. (2022) · Microbiology and Immunology · doi:10.1111/1348-0421.13039 · Cited by 8
“FK506 (tacrolimus), a calcineurin inhibitor, is an immunosuppressant agent intended to prevent allograft rejection in patients who undergo organ transplantation.(15) It binds to its immunophilin FKBP12 to form the FK506–FKBP12 complex that inhibits calcineurin.”
Backgroundvon Samson‐Himmelstjerna, F. A., Messtorff, M. L., Kakavand, N., Eisenberger, U., Korth, J., Lange, U., Kolbrink, B., Aldag, L., Dieckhoff, T. S., Feldkamp, T., et al. (2023) · Transplant International · doi:10.3389/ti.2023.11027 · Cited by 9
“Low tacrolimus levels lead to insufficient immunosuppression with the risk of graft rejection, whereas high levels can have nephrotoxic effects and increase the risk of opportunistic infections (5).”
BackgroundHERV reactivation by adenovirus infection is associated with viral immune regulation
Liang, W., Stubbe, M., Pleninger, L., Hofferek, A., Stubbe, H. C., Mai, J., Özer, S., Frishman, D., Schreiner, S., & Vincendeau, M. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2024.105466 · Cited by 9
Ohara, M., Ozaki, K., Ohkubo, T., Yamada, A., Numasawa, Y., Tanaka, K., Tomii, S., Ishibashi, S., Sanjo, N., & Yokota, T. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9167-17 · Cited by 7
“TAC binds to the FK-binding protein (FKBP) in helper T cells (4); this complex acts on intracellular phosphatase calcineurin, and subsequently inhibits the activation of nuclear factor of activated T cells (NFAT), resulting in the suppression of cytokine production (e.”
BackgroundInfluentialHelmschrott, M., Rivinius, R., Bruckner, T. M., Katus, H. A., & Doesch, A. O. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s135503 · Cited by 7
“Although both CNIs suppress the immune system via a similar mechanism, differences in their side-effect profile can be observed.(3,9) One important reason for the better renal function parameters in patients on tacrolimus (TAC)-based immunosuppression can possibly be explained by the 100 times lower serum concentratio…”
TCR signaling via NFATc1 constrains IL-15-induced bystander activation of human memory CD8+ T cells
Lee, H., Kim, S., Kim, S.-H., Jeong, S., Kim, K. H., Kim, C. G., Koh, J., Kim, H., Han, J. W., Yu, H., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.002 · Cited by 15
Walcher, L., Müller, C., Hilger, N., Kretschmer, A., Stahl, L., Wigge, S., Rengelshausen, J., Müller, A. M., & Fricke, S. (2018) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.18-0056 · Cited by 7
“Nevertheless, adverse effects of csa could be shown in previous studies in humans and rodents and include organ damage to the liver and kidney [4, 10, 15], hypertension [45] and several other toxicities [14].”
BackgroundMasoumi, H. T., Sadeghi, K., & Hadjibabaie, M. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219869442 · Cited by 6
“Both cyclosporine and tacrolimus may cause numerous adverse effects which can range from mild to severe life-threatening reactions including nephrotoxicity, hypertension, neurotoxicity, hyperlipidemia, hyperuricemia, hyperkalemia, hypomagnesemia, diabetes mellitus, and allergic reactions.(5,6) It has been”
BackgroundNovel Immunomodulatory Approaches for Porcine Islet Xenotransplantation
Hong, S., Kim, H. J., Kang, S., & Park, C. (2021) · Current Diabetes Reports · doi:10.1007/s11892-020-01368-y · Cited by 6
Heat shock protein 90 is a new potential target of anti-rejection therapy in allotransplantation
Maehana, T., Tanaka, T., Hashimoto, K., Kobayashi, K., Kitamura, H., & Masumori, N. (2022) · Cell Stress and Chaperones · doi:10.1007/s12192-022-01272-2 · Cited by 6
“Immunosuppressive regimens with withdrawal or avoidance of these agents have been tried, but have not yet been standardized (Azzi et al. 2013; Camilleri et al. 2016; Luan et al. 2009).”
BackgroundSatake, M., Sakuraba, H., Hiraga, H., Yoshida, S., Akemoto, Y., Ota, S., Murai, Y., Hasui, K., Kawaguchi, S., Kikuchi, H., et al. (2022) · In Vivo · doi:10.21873/invivo.12880 · Cited by 6
Ialongo, C., Sapio, M., & Angeloni, A. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001009 · Cited by 6
“12 In brief, 200 mL of the well-mixed whole blood sample was added to the HM within the Dimension EXL 200 instrument to undergo the following: (1) lysis by sonication and buffer (surfactant plus FK506-binding protein competing agent), (2) addition of anti-SRL-antibody-beta-galactosidase conjugate solution plus SRL-coa…”
MethodPeddi, V. R., Marder, B. A., Gaite, L., Oberholzer, J., Goldberg, R. J., Pearson, T. C., Yang, H. C., Allamassey, L., Polinsky, M. S., & Formica, R. N. (2023) · Transplantation Direct · doi:10.1097/txd.0000000000001419 · Cited by 6
Abass, H. A., Al-Tamimi, K. F., Al-Tamimi, D. J., & Ibraheem, J. J. (2020) · Scientia Pharmaceutica · doi:10.3390/scipharm88010012 · Cited by 6
“The early impressive and promising results for using cyclosporine in kidney transplantation led to the subsequent usage of the drug in other organ transplant patients and for the treatment of many and different autoimmune diseases [2].”
BackgroundAlonso‐Guallart, P., Llore, N. P., Lopes, E., Kofman, S.-B., Ho, S.-H., Stern, J. M., Gillotay, P., Bruestle, K., Tang, Q., Sykes, M., et al. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13537 · Cited by 8
Synthetic pharmacotherapy for lupus nephritis
Moroni, G. L., & Ponticelli, C. E. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1276563 · Cited by 6
“Clinically, CsA-associated chronic nephropathy is characterized by arterial hypertension and progressive deterioration of renal function [58].”
BackgroundUltraviolet-induced alloantigen-specific immunosuppression in transplant immunity
Hori, T., Kuribayashi, K., Saito, K., Wang, L., Torii, M., Uemoto, S., Iida, T., Yagi, S., & Kato, T. (2015) · World Journal of Transplantation · doi:10.5500/wjt.v5.i1.11 · Cited by 5
Achilonu, O., Obaido, G., Ogbuokiri, B., Aruleba, K., Musenge, E., & Fabian, J. (2024) · Frontiers in Digital Health · doi:10.3389/fdgth.2024.1427845 · Cited by 6
“…transplant maintenance immunosuppression therapy are described (i) from 1966 to 1983 using combined azathioprine and cortisone; (ii) from 1983 to 2000 replacing azathioprine with cyclosporine; and (iii) starting in 2001, the introduction of sirolimus, everolimus, and mycophenolate mofetil (9 – 11).”
MethodDaca, A., Gołębiewska, J., Bronk, M., & Jarzembowski, T. (2021) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-021-03150-y · Cited by 5
Kamata, Y., Kato, R., Tominaga, M., Toyama, S., Komiya, E., Utsumi, J., Kaneko, T., Suga, Y., & Takamori, K. (2024) · JID Innovations · doi:10.1016/j.xjidi.2024.100271 · Cited by 5
Ishiwata, Y., Nagata, M., Arai, T., Makiishi, M., Yoshikawa, M., Takahashi, H., Kohsaka, H., & Yasuhara, M. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000335 · Cited by 5
Wei, X., Zhu, D., Feng, C.-C., Chen, G., Mao, X., Wang, Q., Wang, J., & Liu, C. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6706 · Cited by 5
“Clinical studies have found that CsA induces hyperglycemia and decreased plasma insulin levels in organ transplant patients (3-5).”
BackgroundKerr, S. M., Jorgensen, N. W., Hong, B. J., Friedland‐Little, J. M., Albers, E. L., Newland, D. M., Law, Y. M., & Kemna, M. S. (2019) · Pediatric Transplantation · doi:10.1111/petr.13616 · Cited by 5
Drugs Used in Rheumatic Disease
Padjen, I. (2018) · Technical report · doi:10.1016/b978-0-444-63887-8.00003-7 · Cited by 6
Cañizares, S., Montalvan, A., Eckhoff, D. E., Sureshkumar, K. K., & Chopra, B. (2025) · Clinical Transplantation · doi:10.1111/ctr.70075 · Cited by 4
Metadata
- Authors
- Azzi, J. R., Sayegh, M. H., & Mallat, S. G.
- Affiliations
- Brigham and Women's Hospital (US)
- American University of Beirut (LB)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12
- Volume
- 191
- Issue
- 12
- Pages
- 5785-5791
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1592567691
- Cited by
- 337
- References
- 90
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 26 · 2023: 32 · 2022: 44 · 2021: 38 · 2020: 27 · 2019: 27 · 2018: 25 · 2017: 17 · 2016: 25 · 2015: 14 · 2014: 12
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- calcineurin inhibitors, cyclosporine, tacrolimus, organ transplantation, immunosuppression, nephrotoxicity, drug toxicity reduction, autoimmune disease therapy, mechanism of action
- MeSH terms
- Animals, Autoimmune Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Drug Therapy, Combination, Forecasting, Graft Rejection, Humans, Immunosuppressive Agents, Kidney Diseases, Lymphocyte Activation, T-Lymphocytes, Meta-Analysis as Topic, Multicenter Studies as Topic, Kidney Transplantation, Randomized Controlled Trials as Topic, Tacrolimus, Cyclosporine, Calcineurin, History, 20th Century, History, 21st Century, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.